Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) ended 2025 with revenue of $17.3 billion, up 4% from $16.5 billion in 2024. GAAP net earnings per share was $2.93, above the analysts’ expectations of $2.65 per share. The share price was down 3% in pre-market trading.
Teva issued full guidance for 2026 of $16.4-16.8 billion revenue, EBITDA of $5-5.3 billion. And earnings per share of $2.55-2.65. The 2026 revenue forecast is lower than the analyst consensus, with the mid-range of the earnings per share forecast also low.
RELATED ARTICLES
Teva beats analysts on Q3, raises guidance
Teva collaborates on skin disease treatment, releases targets
The man behind the exit that Teva missed
Teva had already provided an indication of the 2025 results when it reported a few weeks ago that revenue this year would be close to the lower end of its previous forecasts ($16.8-17 billion), while net income per share would be close to the upper end ($2.55-2.65) and free cash flow ($1.6-1.9 billion). At the same time, Teva also released preliminary forecasts for the coming years.
In the fourth quarter, Teva reported revenue of $4.7 billion with non-GAAP earnings per share of $0.96, above analysts’ expectations. GAAP net profit was $480 million and non-GAAP net profit was $1.1 billion in the fourth quarter.
Teva, managed by CEO Richard Francis, has a market cap of $37.3 billion, after a 4.2% increase in the share price since the beginning of the year.
Published by Globes, Israel business news – en.globes.co.il – on January 28, 2026.
© Copyright of Globes Publisher Itonut (1983) Ltd., 2026.
-1024x683.jpg "Trump, Congress, and the FISA Fiasco")
-1024x683.jpg "Strait Outta Hormuz: Getting the Iran Oil Story Straight")
